<SEC-DOCUMENT>0002060755-26-000002.txt : 20260105
<SEC-HEADER>0002060755-26-000002.hdr.sgml : 20260105
<ACCEPTANCE-DATETIME>20260105172550
ACCESSION NUMBER:		0002060755-26-000002
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260105
FILED AS OF DATE:		20260105
DATE AS OF CHANGE:		20260105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		26507915

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k-20260105.htm
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXY7CNC5JSVVFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE>UNITED STATES</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:64.8pt;width:482.4pt><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>UNITED STATES</B><BR><B>SECURITIES AND EXCHANGE COMMISSION</B><BR><B>Washington, D.C. &nbsp;20549</B></P>
<P align=center style='font:14pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>FORM 6-K</B></P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>For the month of <B>January 2026</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Commission File No. <B>001-40997</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><FONT style='font-size:13pt;border-bottom:1px solid #000000'><B>BRIGHT MINDS BIOSCIENCES INC.</B></FONT><BR>(Translation of registrant's name into English)</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=middle style=width:246.6pt><P align=center style='font:11pt Times New Roman;margin:0'><B>400 N Aberdeen St Suite 900</B><BR><FONT style='border-bottom:1px solid #000000'><B>Chicago, IL 60642</B></FONT><BR>(U.S. Corporate headquarters)</P>
</TD><TD valign=middle style=width:246.6pt><P align=center style='font:11pt Times New Roman;margin:0'><B>1122 Mainland St #228</B><BR><FONT style='border-bottom:1px solid #000000'><B>Vancouver, BC V6B 5L1</B></FONT><BR>(Canadian Corporate headquarters)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Form 20-F&#160;&#160;[ ] &nbsp;<B>Form 40-F&#160;&#160;[ X ]</B></P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=center style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'><A name=_DV_M0 />&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'><B>SUBMITTED HEREWITH</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'>&nbsp;</P>
<TABLE align=center style=border-collapse:collapse;width:475.45pt><TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:5.4pt;color:#000000'><FONT style='border-bottom:1px solid #000000'><B>Exhibits</B></FONT></P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:4.5pt;margin-right:7.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:5.4pt;color:#000000'>99.1</P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:2.6pt;margin-right:1.95pt;color:#000000'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=ex991-20260105.htm style=text-decoration:none>News Release dated </A><A href=ex991-20260105.htm style=text-decoration:none>January</A><A href=ex991-20260105.htm style=text-decoration:none> </A><A href=ex991-20260105.htm style=text-decoration:none>5</A><A href=ex991-20260105.htm style=text-decoration:none>, 202</A><A href=ex991-20260105.htm style=text-decoration:none>6</A></FONT></P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>SIGNATURE</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><B>BRIGHT MINDS BIOSCIENCES INC.</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><FONT style='border-bottom:1px solid #000000'><I>/s/ Ryan Cheung</I></FONT><KBD style='display:inline-block;width:106.65pt;border-bottom:1px solid #000000'>&nbsp;</KBD>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:216pt'>Ryan Cheung<BR>Chief Financial Officer</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Date:  January 5, 2026</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-20260105.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXY7CNC5JSVVFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:14pt Aptos;margin:0'><FONT style='font-family:Calibri'><B>For Immediate Release</B></FONT></P>
<P align=center style='font:14pt Aptos;margin-top:12pt;margin-bottom:0pt'><FONT style='font-family:Calibri'><B>Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026</B></FONT></P>
<P align=center style='font:8pt Aptos;margin:0'>&nbsp;</P>
<P align=center style='font:12pt Aptos;margin:0;margin-left:2.25pt'><FONT style='font-family:Calibri'>&#8211; Conference Call and Live Webcast at 8AM ET &#8211;</FONT></P>
<P align=center style='font:12pt Aptos;margin:0;text-indent:-18pt;margin-left:20.25pt'>&#45;</P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>NEW YORK CITY and VANCOUVER, British Columbia, January 5, 2026 &nbsp;&#8211; Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (&#8220;Bright Minds&#8221; or the &#8220;Company&#8221;), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy.</FONT></P>
<P style='font:12pt Aptos;margin:0'>&nbsp;</P>
<P align=justify style='font:12pt Aptos;margin-top:0pt;margin-bottom:5pt;background-color:#FFFFFF'><FONT style='font-family:Calibri'><B>Webcast Information</B></FONT></P>
<P align=justify style='font:12pt Aptos;margin-top:0pt;margin-bottom:5pt;background-color:#FFFFFF'><FONT style='font-family:Calibri'>The Bright Minds virtual event will be webcast live and a replay will be available after the event by visiting the &#8220;Investors&#8221; section of the Company&#8217;s website and selecting &#8220;Events and Presentations.&#8221;</FONT></P>
<P align=justify style='font:11pt Aptos Body;margin:0;color:#1C262C'><FONT style='font-family:Calibri'><B>Date and Time: </B>January 6, 2026, 8AM ET<B> </B></P>
<P align=justify style='font:11pt Aptos Body;margin:0'><FONT style=color:#1C262C><FONT style='font-family:Calibri'><B>Webcast:</B><B> </B></FONT><FONT style='font-family:Calibri'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>https://app.livestorm.co/bright-minds-biosciences/bmb-101-topline-data-announcement</FONT></P>
<P style='font:12pt Aptos Body;margin:0'>&nbsp;</P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>The call will include a discussion of the data followed by a Q&amp;A session. Individuals who wish to ask questions should use the &#8220;Questions&#8221; tab available during the live webcast.</FONT><FONT style=font-family:Arial>&#8203;</FONT></P>
<P style='font:12pt Aptos;margin:0'>&nbsp;</P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'><B>About Bright Minds Biosciences</B></FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including Rare Epilepsy, Prader-Willi Syndrome, Depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.</FONT></P>
<P style='font:12pt Aptos;margin:0'>&nbsp;</P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.</FONT><FONT style=font-family:Arial>&#8203;</FONT></P>
<P style='font:12pt Aptos;margin:0'>&nbsp;</P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'><B>Contact</B></FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>Alex Vasilkevich</FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>Chief Operating Officer</FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>Bright Minds Biosciences Inc.</FONT></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>T: 414-731-6422</FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>E: alex@brightmindsbio.com</FONT></P>
<P style='font:12pt Aptos;margin:0'>&nbsp;</P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'><B>Investor Relations</B></FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>Lisa M. Wilson</FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>T: 212-452-2793</FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style='font-family:Calibri'>E: lwilson@investorrelations.com</FONT></P>
<P style='font:12pt Aptos;margin:0'><FONT style=font-family:Arial>&#8203;</FONT></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
